Artichoke

Cynara cardunculus L. belongs to Asteraceae (Compositae), the daisy or aster family, and NCBI Taxonomy files the globe artichoke as Cynara cardunculus var. scolymus, taxon 59895. The species is diploid (2n = 34) and mostly cross-pollinated, and Sonnante and colleagues (Annals of Botany 2007) describe three closely related forms: the wild cardoon (var. sylvestris), recognized as the ancestor of the other two; the globe artichoke, selected for large, non-spiny flower heads; and the leafy or cultivated cardoon (var. altilis), selected for tender, thick-stalked leaves. For centuries the artichoke was treated as a separate species, Cynara scolymus L., and that name still appears on many labels and in most clinical trials; the European Pharmacopoeia and EMA now use Cynara cardunculus, keeping Cynara scolymus as a synonym. Wild cardoon grows across the Mediterranean basin, from Cyprus and the Black Sea in the east to Gibraltar, Atlantic Spain, and Portugal in the west, and Britannica describes the artichoke as native to the western and central Mediterranean and North Africa. The Jerusalem artichoke (Helianthus tuberosus), grown for its edible tubers, is an unrelated plant that does not resemble it.

The globe artichoke is a large, thistle-like perennial. EMA’s assessment report describes plants 1.5–2 m tall with arching, deeply lobed, silvery glaucous-green leaves 50–80 cm long, and Britannica notes a rosette of deeply toothed leaves up to a meter long that die back each year after the plant flowers. Sturdy branched stalks carry about three to five large buds, each 8–15 cm across and covered in numerous triangular scales, the involucral bracts. Botanically each bud is a capitulum, a compound flower head made of many tiny florets on a broad base. The edible parts are the fleshy lower ends of the bracts and that base, the ‘heart’; the mass of immature florets in the center is the inedible ‘choke’. Left unpicked, the bud opens into a striking thistle-like head of numerous small purple florets. Traditionally the artichoke is mostly propagated vegetatively and grown as a perennial, while cardoons are raised from seed (Sonnante); in California, though, most artichokes are now planted annually, many as nursery-raised seedlings (California Foundation for Agriculture in the Classroom).

The medicinal part is the leaf. The European Pharmacopoeia defines artichoke leaf as the dried basal leaves, containing at least 0.8% chlorogenic acid (EMA). EMA lists phenolic acids at up to 2%, chiefly caffeoylquinic acids: chlorogenic acid (PubChem CID 1794427, C16H18O9) and cynarin (CID 5281769, C25H24O12), which PubChem identifies as 1,3-dicaffeoylquinic acid; flavonoids at 0.1–2%, mainly glycosides of luteolin such as scolymoside and cynaroside (luteolin-7-glucoside); and about 0.4% bitter sesquiterpene lactones, of which 47–83% is cynaropicrin (CID 119093). Cynaropicrin is most concentrated in young leaves and absent from the root and from fully developed flowers and fruits, which is why a leaf tea is far more bitter than a cooked heart. Ključevšek and Kreft (Health Science Reports 2025) note that sesquiterpene lactones are among the key sensitizers in the daisy family, able to irritate and inflame skin and, in sensitized people, to cause reactions when swallowed. The leaf also contains phytosterols, tannins, and inulin, and the globe vegetable is a notable source of inulin-type fructans: extracts made from bracts and stems left over from processing contained about 70% of these indigestible sugar chains (Zeaiter and colleagues, BioMed Research International 2019).

Artichoke and cardoon are both domesticated forms of the wild cardoon, but when and where that happened is still debated. Weighing historical, linguistic, artistic, and genetic evidence, Sonnante and colleagues conclude that the artichoke was apparently domesticated in Roman times, possibly in Sicily, and spread by the Arabs in the early Middle Ages, while the cardoon was domesticated later in the western Mediterranean. Classical sources are slippery. The Greek word scolymos simply meant spiny and could refer to other thistles; one twentieth-century scholar read Theophrastus as reporting artichokes cultivated in Sicily but not in Greece; and Columella, in the first century AD, described a cultivated ‘cinara’ that was still spiny, with a head whose tip pricked. A genetic study of wild and cultivated plants from southern Europe and North Africa by Gatto and colleagues (Annals of Botany 2013) supported two separate domestication events, one for each crop, and proposed southern Italy, probably Sicily, as the artichoke’s center of origin. Britannica adds that the plant reached the eastern Mediterranean in ancient times but was then valued for its young leaves rather than its flower heads.

Britannica says the edible flower form was first recorded in Italy about 1400, and Sonnante and colleagues date the first certain record of the artichoke trade to the early fifteenth century, when Filippo Strozzi traded artichokes from Sicily to Florence. The names trace its route. Italian carciofo, Spanish alcachofa, and Portuguese alcachofra come from the Arabic al harshuff, while the English, French, and German names derive from old Italian forms such as articiocco, suggesting that Italy was the bridge to the rest of Europe. Artichokes appear in Renaissance paintings by Vincenzo Campi and in Giuseppe Arcimboldo’s fantastical vegetable portraits. EMA’s assessment report repeats the traditional stories that globe artichokes were first cultivated near Naples in the middle of the fifteenth century, were introduced to France by Catherine de’ Medici, and were growing in Henry VIII’s garden at Newhall by 1530. Medicinally, the same report says the leaf has been used in European medicine as a choleretic, a remedy that increases bile flow, and as a diuretic since Roman times, and it records folk uses from Europe to Brazil, Haiti, and Mexico for the liver, gallbladder, digestion, and cholesterol.

Artichoke leaf became a mainstream pharmacy product in twentieth-century Europe. EMA records leaf extracts on the market in France since 1976 and in Germany since 1978, and leaf teas in Spain since 1973, sold for indigestion, sluggish bile flow, and sometimes cholesterol, and notes that Germany’s Commission E reported its choleretic activity. The leaf’s bitterness also found a place behind the bar: EMA notes that alcoholic leaf extracts are used to make bitter liqueurs, at about 10 g of dried leaf per liter. Campari Group, which now owns the brand, says Angelo, Amedeo, and Mario Dalle Molle launched Cynar in Padua in 1952, an infusion of 13 herbs and botanicals including artichoke whose recipe remains secret. In the United States, Italian immigrants planted California’s first commercial artichoke fields near Half Moon Bay in the late nineteenth century, according to the California Foundation for Agriculture in the Classroom, and the modern industry began in the 1920s around Castroville, the self-proclaimed ‘Artichoke Center of the World’. California grows virtually all of the nation’s commercial artichokes, about 68% of them in Monterey County, and declared the artichoke its official state vegetable in 2013.

The traditional explanation for artichoke’s digestive effect is choleresis: an increase in the flow of bile, the fluid the liver makes to help digest fats. EMA’s assessment report summarizes laboratory evidence that leaf extracts increase bile secretion in cultured liver cells and in isolated rat livers, where expressed juice raised bile flow by up to 150%, with mono- and dicaffeoylquinic acids the most active fractions. Findings with single compounds have been inconsistent, and in one rat study pure cynarin and chlorogenic acid showed no choleretic effect at all. The key human evidence is a small crossover pilot study by Kirchhoff and colleagues (Phytomedicine 1994). In 20 volunteers, a single 1.92 g dose of a standardized extract, given through a tube directly into the duodenum, increased bile secretion by 127% after 30 minutes, 152% after 60 minutes, and 94% after a further hour, significantly more than placebo, with no side effects. EMA’s herbal committee kept bile-duct obstruction, gallstones, and other biliary disorders as outright contraindications precisely because this study shows that the extract stimulates bile secretion in people.

For cholesterol, the leading laboratory explanation comes from Gebhardt (Journal of Pharmacology and Experimental Therapeutics 1998). In rat liver cells grown in culture, high-dose water extracts of artichoke leaf inhibited the production of cholesterol by about 20% at low concentrations and more strongly at the highest concentration tested. The block appeared to act at HMG-CoA reductase, the enzyme that statins target, but indirectly: the extracts did not inhibit the enzyme itself, the effect built up over time and was fully reversible within 20 hours of removing the extract, and it blocked insulin’s stimulation of the enzyme. When individual constituents were screened, the flavonoid cynaroside and especially luteolin, the same molecule without its sugar, were mainly responsible, chlorogenic acid was much weaker, and cynarin had no significant effect, which undercuts the old idea that cynarin is the active principle. In a human liver cell line, Gebhardt (Phytotherapy Research 2002) found the extract only moderately active unless an enzyme first freed luteolin from cynaroside, a reminder that metabolism shapes what reaches the target. EMA concludes that rigorous trials are still needed to establish artichoke as a cholesterol-lowering agent.

Artichoke is also promoted as an antioxidant and liver-protective herb, and here the evidence is almost entirely from laboratory and animal work. In rat liver cells exposed to damaging peroxides, leaf extract and several constituents, including caffeic acid, chlorogenic acid, cynarin, and cynaroside, reduced markers of fat oxidation and cell injury (Gebhardt and Fausel, cited by EMA); in rats, extracts given before poisoning with carbon tetrachloride lowered liver enzymes, and older experiments reported faster liver regeneration after partial removal of the liver. Laboratory work also describes antispasmodic effects on guinea pig intestine, and oral extracts modestly increased gut propulsion in rats, findings that fit the traditional use for fullness and bloating. In rats given cynarin intravenously, more cholesterol was excreted in bile (EMA), another possible route to lower blood cholesterol that has not been shown in people. EMA states plainly that the liver-protective and regenerating effects documented for cynarin in test tubes and rats have not yet been documented in clinical studies. Activity in a dish or a rat is a reason to run trials, not evidence that a capsule works.

Indigestion (functional dyspepsia) is the best-studied use. Holtmann and colleagues (Alimentary Pharmacology and Therapeutics 2003) enrolled 247 people with functional dyspepsia, meaning recurring upper-abdominal symptoms without an ulcer or other structural cause, in a double-blind, multicenter, placebo-controlled trial. Participants took a commercial artichoke leaf extract, two 320 mg capsules three times a day (1,920 mg daily), or placebo for six weeks. Among the 244 analyzed, overall symptom improvement was significantly greater with the extract (a score of 8.3 against 6.7 with placebo), and disease-specific quality of life on the Nepean Dyspepsia Index also improved more. Báez and colleagues (Cochrane 2023), reviewing 41 trials of 27 non-Chinese herbal medicines for functional dyspepsia, listed artichoke among the herbs that may improve symptoms, but because the finding rests on this single trial they graded the certainty of evidence as low. EMA reviewed the same evidence and concluded that artichoke leaf may improve symptoms of indigestion, but that firm conclusions could not be drawn because the studies were poorly designed, small, and short.

Earlier and larger studies were uncontrolled. In an open, dose-ranging postal study by Marakis and colleagues (Phytomedicine 2002), 516 otherwise healthy adults with self-reported indigestion took 320 or 640 mg of leaf extract a day for two months; among the 454 who finished, global dyspepsia scores fell by an average of 40%, with no difference between the two doses. Without a placebo group such improvements cannot be separated from natural recovery and expectation, and the lack of a dose effect is another reason for caution. EMA also summarizes post-marketing surveillance studies of 417 to 557 patients with indigestion or liver and bile-duct complaints, in which the extract was well tolerated. Combination products are a separate question. Giacosa and colleagues (Evidence-Based Complementary and Alternative Medicine 2015) found that capsules combining ginger and artichoke extracts improved symptoms, including nausea, fullness, upper-abdominal pain, and bloating, more than placebo in 126 people with functional dyspepsia over four weeks, but that result cannot be credited to artichoke alone.

Irritable bowel syndrome (IBS) has only uncontrolled data. In a post-marketing surveillance study, Walker and colleagues (Phytotherapy Research 2001) identified a subgroup with IBS symptoms among people taking the extract for indigestion over six weeks; symptom severity fell significantly, 96% rated it at least as good as previous treatments, and the authors concluded that a controlled trial was justified. Bundy and colleagues (Journal of Alternative and Complementary Medicine 2004) then reanalyzed the Marakis study, identifying 208 participants with IBS after the fact. After two months, the proportion meeting IBS criteria fell by 26.4%, reported bowel habit shifted away from alternating constipation and diarrhea toward normal, and dyspepsia symptom scores fell by 41%. These are interesting signals, but an open design and a subgroup chosen after the fact cannot show that artichoke works for IBS, and we found no published placebo-controlled trial in IBS. EMA’s traditional indication covers bloating and wind with indigestion rather than IBS itself.

Cholesterol trials vary widely in size and quality. Englisch and colleagues (Arzneimittel-Forschung 2000) randomized 143 adults with total cholesterol above 280 mg/dL to 1,800 mg a day of a fresh-leaf extract or placebo for six weeks; total cholesterol fell 18.5% against 8.6% with placebo, and LDL cholesterol 22.9% against 6.3%. A UK trial was more sobering. Bundy and colleagues (Phytomedicine 2008) gave 75 otherwise healthy adults with mildly to moderately raised cholesterol 1,280 mg a day of a standardized extract or placebo for 12 weeks: total cholesterol fell 4.2% with artichoke and rose 1.9% with placebo, a modest but significant difference, with no difference in LDL, HDL, or triglycerides. Wider and colleagues (Cochrane 2013) found three eligible trials with 262 participants and concluded that artichoke showed potential but that the evidence was not yet convincing; Cochrane withdrew the review in 2016, explaining that its heart group considered the topic a low priority. Sahebkar and colleagues (Critical Reviews in Food Science and Nutrition 2018) pooled nine trials with 702 participants and found total cholesterol 17.6 mg/dL, LDL 14.9 mg/dL, and triglycerides 9.2 mg/dL lower than in controls, with no change in HDL and larger LDL effects in people with higher starting levels.

Fatty liver and blood pressure: Panahi and colleagues (Phytotherapy Research 2018) randomized 100 adults with fatty liver on ultrasound to 600 mg of leaf extract a day or placebo for two months; among the 90 who finished, liver enzymes, liver size on ultrasound, and blood fats improved more with artichoke, although HDL cholesterol also fell. Rangboo and colleagues (International Journal of Hepatology 2016) reported similar enzyme and lipid improvements in 60 people with NASH taking 2,700 mg a day. But in the 2026 SteatoChoke pilot by Holländer and colleagues (Journal of Clinical Lipidology), 40 people with obesity awaiting bariatric surgery had less liver fat after six weeks on artichoke, yet their liver enzymes, particularly AST, rose. For blood pressure, Amini and colleagues (Clinical Nutrition Research 2022) pooled seven small trials with 472 participants and found systolic pressure about 2 mmHg lower. Overall, artichoke leaf has one solid positive trial in indigestion, a modest and inconsistent cholesterol effect, and early liver data based on blood tests and scans; none of it shows fewer heart attacks or less liver scarring.

EMA’s monograph covers six leaf preparations for adults and adolescents over 12, all for traditional use in indigestion. As a tea, it gives 1.5 g of the cut dried leaf in 150 ml of boiling water four times a day, or 3 g in 150 ml once or twice a day, for a daily total of 3–6 g. Powdered dried leaf is taken at 600–1,500 mg a day in two to four divided doses. Water-based dry extracts of dried leaf (drug-to-extract ratio 2–7.5:1) are dosed at 200–640 mg per dose and 400–1,320 mg a day, and the more concentrated dry extracts of fresh leaf (15–35:1) at 200–900 mg per dose and 600–2,700 mg a day; two soft extracts complete the list. EMA advises seeing a doctor if symptoms last more than two weeks. Trials used amounts within or near these ranges: 1,920 mg of extract a day in the Holtmann dyspepsia trial, 1,280 mg in the Bundy cholesterol trial, 1,800 mg in the Englisch trial, and 600 mg in the Panahi fatty liver trial.

Products are not interchangeable. The drug-to-extract ratio tells you how much leaf went into each unit of extract, so 300 mg of a 25–35:1 fresh-leaf extract represents far more plant material than 300 mg of powdered leaf, and extracts made with water or with dilute alcohol differ again. The European Pharmacopoeia requires artichoke leaf to contain at least 0.8% chlorogenic acid, and some European products are standardized to caffeoylquinic acids; a label that names the leaf, the extract ratio, and the daily dose makes it possible to compare a product with the research. Artichoke is also sold in multi-ingredient digestive, liver, and cholesterol formulas. Cochrane excluded combination products from its cholesterol review, and the ginger and artichoke trial shows that results from mixtures cannot be credited to one ingredient. Eating artichokes is a different matter again: Britannica calls them a rich source of potassium, vitamin C, and dietary fiber, but the cooked heart is not the leaf extract used in trials and contains little of the bitter cynaropicrin concentrated in young leaves.

Practical points: artichoke leaf is very bitter, which helps explain why tablets and capsules are more popular than tea. For indigestion, EMA’s two-week threshold for seeing a doctor is a sensible checkpoint, although the main trial measured its effect over six weeks. For cholesterol, the effects seen in trials appeared over six to twelve weeks, so a lipid test before and after is the only way to know whether it is doing anything, and it should never replace a statin or other prescribed treatment. Anyone with gallstones, a history of biliary colic, or liver disease should talk to a doctor before taking it, and anyone allergic to ragweed, chamomile, arnica, or other daisy-family plants should avoid it, as EMA advises. Single-ingredient products are easier to judge than blends, because if a side effect appears you know which plant caused it.